Orexigen Therapeutics, Inc. (OREX) Reaches $0.91 1 Year Low; Cti Industries (CTIB)’s Sentiment Is 0.67

February 11, 2018 - By Vivian Park

CTI Industries Corporation develops, produces, and sells consumer and film products for commercial and industrial applications worldwide. The company has market cap of $16.57 million. The firm offers novelty products, including foil balloons, such as Superloons, Ultraloons, Miniloon, Card-B-Loons, Shape-A-Loons, and mini shapes; latex balloons primarily under the Partyloons name; toy balloon products, which include punch balls, water bombs, and Animal Twisties; Candy Blossoms that are containers with candy items and air-inflated balloons; and other inflatable toy items. It has a 104.44 P/E ratio. It also provides vacuum sealable bags and rolls of film for household storage under the Ziploc and Zipvac brand names; valved and resealable bags for vacuum storage use; and vacuum sealing machines under the brand name of Ziploc.

The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) hit a new 52-week low and has $0.86 target or 6.00% below today’s $0.91 share price. The 7 months bearish chart indicates high risk for the $15.11 million company. The 1-year low was reported on Feb, 11 by Barchart.com. If the $0.86 price target is reached, the company will be worth $906,540 less. The stock decreased 2.93% or $0.0275 during the last trading session, reaching $0.91. About 173,487 shares traded. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 15.00% since February 11, 2017 and is downtrending. It has underperformed by 31.70% the S&P500.

Since January 1, 0001, it had 1 buy, and 0 insider sales for $8,400 activity.

The stock decreased 4.88% or $0.241 during the last trading session, reaching $4.7. About 1,023 shares traded. CTI Industries Corporation (CTIB) has risen 31.49% since February 11, 2017 and is uptrending. It has outperformed by 14.79% the S&P500.

Perritt Capital Management Inc holds 0.1% of its portfolio in CTI Industries Corporation for 94,700 shares. Blackrock Inc. owns 230 shares or 0% of their US portfolio. Moreover, James Investment Research Inc has 0% invested in the company for 800 shares. The New York-based Morgan Stanley has invested 0% in the stock. Northern Trust Corp, a Illinois-based fund reported 19,524 shares.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. The company has market cap of $15.11 million. It offers Contrave for the treatment of obesity. It currently has negative earnings. The firm also offers Contrave under the Mysimba brand name.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: